National Institutes of Health

Description

The purpose of this Funding Opportunity Announcement (FOA) is to complete treatment of the participants recruited into the Preventing Early Renal Loss in Diabetes (PERL) Study and to analyze the outcomes of the trial. PERL is a randomized, double-blind trial to test whether the medication, allopurinol, can slow the progression of kidney disease in people with type 1 diabetes and early diabetic kidney disease.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• For-profit organizations other than small businesses
• Small businesses
• Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV